Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Hexarelin: Evidence Summary
Evidence summary for Hexarelin across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Hexarelin overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Growth hormone secretion | Tier B | 7 | Potent GHS-R1a agonist with consistent GH release in dose-response studies |
| Cardioprotection | Tier C | 2 | Improves cardiac function in GH-deficient patients; direct cardiac receptor binding |
References (6)
- Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues. . Pharmacological research (2012) PMID: 22732396
- CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. — Bodart V, et al. . Molecular Cell Endocrinology (2002) PMID: 11988484
- Ghrelin plays a minor role in the physiological control of cardiac function in the rat. . Endocrinology (2003) PMID: 12697684
- Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland. . Journal of endocrinological investigation (2001) PMID: 11227737
- Growth hormone-releasing peptides and their analogs. . Frontiers in neuroendocrinology (1998) PMID: 9465289
- Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man. . Clinical endocrinology (1997) PMID: 9404449